Boxer Capital
MTNB icon

Boxer Capital’s Matinas BioPharma MTNB Stock Holding History

Boxer Capital’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,305
Closed -$8.9M – 98
2021
Q2 		$8.9M Hold
15,305
– – 0.31% 68
2021
Q1 		$12.1M Hold
15,305
– – 0.41% 56
2020
Q4 		$15.6M Hold
15,305
– – 0.5% 49
2020
Q3 		$8.79M Hold
15,305
– – 0.3% 56
2020
Q2 		$8.87M Hold
15,305
– – 0.39% 49
2020
Q1 		$6.89M Buy
15,305
+1,721
+13% +$1.56M 0.47% 45
2019
Q4 		$23.1M Hold
13,584
– – 1.31% 21
2019
Q3 		$6.42M Hold
13,584
– – 0.47% 39
2019
Q2 		$8.73M Hold
13,584
– – 0.75% 25
2019
Q1 		$11.1M Buy
13,584
+6,060
+81% +$4.9M 1.28% 19
2018
Q4 		$3.36M Buy
+7,524
New +$4.43M 0.41% 22

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sargent Investment Group
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Courage Capital Management
Courage Capital Management Nashville, Tennessee $67.3M AUM 9.93% 1-Year Est. Return
Arkadios Wealth Advisors
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
JTC Employer Solutions Trustee
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
GSA Capital Partners
GSA Capital Partners London, United Kingdom $1.59B AUM 39.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boxer Capital's MTNB Position: Q3 2021 in Review

Boxer Capital sold out of Matinas BioPharma (MTNB) in Q3 2021, closing a stake of 15,305 shares — an estimated $8.9M sold.

Boxer Capital first reported a position in MTNB in Q4 2018 and held it in 11 quarters. The position peaked at $23.1M in Q4 2019. 67 funds tracked by Wall St. Rank hold MTNB as of Q3 2021.

  • Boxer Capital reported no remaining Matinas BioPharma position as of Q3 2021 after selling out during the quarter.
  • Boxer Capital sold 15,305 Matinas BioPharma shares in Q3 2021, an estimated $8.9M.
  • Boxer Capital first reported a position in Matinas BioPharma in Q4 2018 and held it in 11 quarters.
  • Boxer Capital's Matinas BioPharma position peaked at $23.1M in Q4 2019.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2021.

Based on Boxer Capital's 13F filing for Q3 2021, filed 15 Nov 2021.